Beijing Jingyuan Bio-Pharmaceutical

Beijing Jingyuan Bio-Pharmaceutical is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of innovative recombinant protein therapeutics. The company utilizes a proprietary high-efficiency protein expression and purification platform to produce complex biologics for regenerative medicine and orthopedics. Its lead product candidate is a recombinant human bone morphogenetic protein-2 (rhBMP-2), which is currently in clinical development for bone defect repair and spinal fusion. Beyond its core orthopedic programs, the company is advancing a pipeline of growth factors, including rhVEGF and rhFGF, to address ischemic diseases and chronic wound healing. Beijing Jingyuan Bio-Pharmaceutical focuses on bridging the gap between laboratory-scale research and large-scale industrial production of high-purity biologics. The company is strategically located in the Beijing Economic-Technological Development Area, benefiting from a robust local biotech ecosystem.